FDA Rejects J&J Petition, OKs Duragesic Generics

Law360, New York (January 31, 2005, 12:00 AM EST) -- The U.S. Food and Drug Administration has rejected petitions to block or delay the approval of generic versions of the Duragesic pain relief patch made by Johnson & Johnson.

Generic drug makers Mylan Laboratories Inc. and Noven Pharmaceuticals received approval for their generic version of Duragesic on Friday.

“The agency's approval is expected to provide patients with access to a lower cost alternative of this pain management system. At the same time that FDA approved Mylan's generic product, it acted on several citizens' petitions requesting that...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.